CytoDyn, Inc. (CYDY)
0.20
0.00 (0.00%)
USD |
OTCM |
Oct 14, 16:00
CytoDyn Net Income (Quarterly) : -19.94M for Aug. 31, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| August 31, 2026 | -19.94M |
| May 31, 2026 | -9.862M |
| February 28, 2026 | -4.69M |
| November 30, 2025 | -22.61M |
| August 31, 2025 | -5.54M |
| May 31, 2025 | -5.956M |
| February 28, 2025 | -4.758M |
| November 30, 2024 | -4.768M |
| August 31, 2024 | 19.23M |
| May 31, 2024 | -16.79M |
| February 29, 2024 | -11.92M |
| November 30, 2023 | -9.563M |
| August 31, 2023 | -11.57M |
| May 31, 2023 | -18.64M |
| February 28, 2023 | -13.70M |
| November 30, 2022 | -26.50M |
| August 31, 2022 | -20.99M |
| May 31, 2022 | -110.43M |
| February 28, 2022 | -41.28M |
| November 30, 2021 | -40.08M |
| August 31, 2021 | -45.34M |
| May 31, 2021 | -65.00M |
| February 28, 2021 | -45.21M |
| November 30, 2020 | -35.42M |
| August 31, 2020 | -30.83M |
| Date | Value |
|---|---|
| May 31, 2020 | -57.61M |
| February 29, 2020 | -35.77M |
| November 30, 2019 | -14.86M |
| August 31, 2019 | -16.16M |
| May 31, 2019 | -14.89M |
| February 28, 2019 | -12.57M |
| November 30, 2018 | -14.31M |
| August 31, 2018 | -14.41M |
| May 31, 2018 | -9.624M |
| February 28, 2018 | -17.95M |
| November 30, 2017 | -10.95M |
| August 31, 2017 | -11.63M |
| May 31, 2017 | -6.830M |
| February 28, 2017 | -8.112M |
| November 30, 2016 | -5.467M |
| August 31, 2016 | -5.354M |
| May 31, 2016 | -6.497M |
| February 29, 2016 | -5.047M |
| November 30, 2015 | -5.265M |
| August 31, 2015 | -8.895M |
| May 31, 2015 | -14.00M |
| February 28, 2015 | -2.722M |
| November 30, 2014 | -4.984M |
| August 31, 2014 | -3.380M |
| May 31, 2014 | -2.996M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 19.94M |
| EPS Diluted (Quarterly) | -0.0147 |
| Enterprise Value | 301.78M |
| Earnings Yield | -22.15% |
| Normalized Earnings Yield | -14.15 |